NYSE:EVMN
Evommune, Inc.
Evommune, Inc.'s revenue grew 85.7% in fiscal 2025 to $13.0M while operating margin rose to −623.6%. Free cash flow was −$76.7M, −589.8% of revenue, and the diluted share count rose 306.9%.Summary generated from Evommune, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$13.0M
Revenue growth+85.7%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−623.6%
Net margin−529.8%
ROICn/a
Return on equity−224.6%
Debt / equityn/a
Free cash flow−$76.7M
FCF margin−589.8%
Share count change+306.9%
Financials
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | 7 | 13 |
| Operating income | −70 | −81 |
| Net income | −67 | −69 |
| Free cash flow | −58 | −77 |
Recent filings
- 8-KRegulation FD disclosure
Oct 1, 2026 - 8-KRegulation FD disclosure
Sep 23, 2026 - 8-KRegulation FD disclosure
Sep 15, 2026 - 8-KRegulation FD disclosure
Sep 9, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KRegulation FD disclosure
Jul 30, 2026 - 4Insider transaction report
Jul 10, 2026